Does Semaglutide Cause Hair Loss? What the 2026 Research Actually Found

"Does Ozempic cause hair loss?" is one of the most-searched questions about GLP-1 drugs, and unlike a lot of side-effect worries that circulate online, this one has a real and fairly fresh evidence base behind it — most of it published in 2026, as dermatologists caught up with a drug class that scaled faster than the safety literature could track it. The honest answer isn't a flat yes or no; it's a specific, mechanistically-explained pattern that the research has only recently mapped in detail.

What the 2026 Systematic Review Found

A 2026 systematic review in Science Progress screened 133 studies and included 24 that met inclusion criteria for evaluating hair loss associated with GLP-1 receptor agonist use¹. Its central finding complicates the simplest explanation people reach for first. The most common assumption is that hair loss on these drugs is purely a byproduct of rapid weight loss itself — a well-established phenomenon in medicine, since any sudden, large weight loss (from any cause, including bariatric surgery or a crash diet) can trigger telogen effluvium, a temporary, diffuse shedding caused by a large number of hair follicles simultaneously shifting into their resting phase. The review confirms rapid weight loss is a real contributor, particularly for telogen effluvium¹.

But the review also found a second pattern that rapid weight loss alone doesn't explain: a dose-dependent relationship specific to semaglutide, where doses below 2 mg weekly were rarely implicated, while the higher doses used specifically for obesity treatment were more commonly associated with reported hair loss¹. That dose-dependency is a meaningful clue — if hair loss were purely a downstream consequence of how much weight someone lost, it wouldn't track with the drug's dose in a pattern independent of weight-loss magnitude. The review identified androgenetic alopecia and telogen effluvium as the predominant hair-loss subtypes, with tirzepatide most frequently linked to telogen effluvium specifically, and semaglutide and tirzepatide showing the highest incidence rates among the GLP-1 class generally¹. Women appeared disproportionately affected across the reviewed literature¹.

Real Numbers From a 2025-2026 Patient Survey

A cross-sectional study of 254 GLP-1 receptor agonist users in Saudi Arabia, conducted January–June 2025, put concrete numbers behind the pattern². Severe hair loss was significantly more common among users of tirzepatide (Mounjaro) — 43.4% — and liraglutide (Saxenda) — 42.9% — compared to other GLP-1 medications in the study². In multivariable analysis, being male was protective (adjusted odds ratio 0.36 relative to female participants, p=0.003), and tirzepatide use specifically carried a significantly elevated odds ratio (3.02) for reporting hair loss². Notably, in this particular study, duration of use was not identified as a significant predictor — meaning hair loss wasn't simply a function of "the longer you're on it, the worse it gets" in this dataset, which is consistent with an early-phase telogen-effluvium-type shedding pattern rather than a slow cumulative one.

The same study's authors describe the hair loss as typically non-scarring and reversible, while emphasizing that it meaningfully affects patients psychologically and can undermine treatment adherence — a real quality-of-life cost even when the underlying prognosis is good².

Why This Matters Beyond the Cosmetic Concern

Dermatology journals took explicit notice of this pattern in 2026 specifically because of how quickly GLP-1 prescribing scaled — a Journal of the American Academy of Dermatology piece framed hair loss as one of several dermatologic effects clinicians needed to get ahead of as GLP-1 use broadened far beyond its original diabetes indication³. That "the prescribing outpaced the specialty literature" framing matters for anyone considering these drugs through the boards on this site — see best semaglutide online and best tirzepatide online — because it means hair loss counseling is a genuinely newer addition to informed-consent conversations than most of the other well-known GLP-1 side effects, and not every prescriber may be current on it. For the broader muscle-and-lean-mass side of what rapid GLP-1-driven weight loss costs the body, see our review of semaglutide and tirzepatide muscle loss.

Bottom Line

GLP-1 drugs are genuinely associated with hair loss, and the mechanism is more specific than "you lost weight fast." A 2026 systematic review of 24 studies found a real dose-dependent signal for semaglutide beyond what rapid weight loss alone would predict, with tirzepatide most consistently linked to telogen effluvium and both drugs showing the highest incidence in the GLP-1 class. A concrete patient survey found severe hair loss reported by over 40% of tirzepatide and liraglutide users in that sample, disproportionately affecting women, and generally described as non-scarring and reversible. That reversibility is the genuinely reassuring part — but "reversible" doesn't mean "not real," and anyone starting a GLP-1 drug at obesity-treatment doses should know this is now a documented, actively-studied effect, not a rare anecdote. Hair isn't the only tissue getting fresh dermatological scrutiny in 2026 — a first-of-its-kind human biopsy study has started mapping what actually drives "Ozempic face" at the cellular level, which we cover in Ozempic face: what actually causes it.